These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 3359437

  • 1. Enhanced melphalan cytotoxicity following buthionine sulfoximine-mediated glutathione depletion in a human medulloblastoma xenograft in athymic mice.
    Skapek SX, Colvin OM, Griffith OW, Elion GB, Bigner DD, Friedman HS.
    Cancer Res; 1988 May 15; 48(10):2764-7. PubMed ID: 3359437
    [Abstract] [Full Text] [Related]

  • 2. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
    Rosenberg MC, Colvin OM, Griffith OW, Bigner SH, Elion GB, Horton JK, Lilley E, Bigner DD, Friedman HS.
    Cancer Res; 1989 Dec 15; 49(24 Pt 1):6917-22. PubMed ID: 2582434
    [Abstract] [Full Text] [Related]

  • 3. Increased melphalan activity in intracranial human medulloblastoma and glioma xenografts following buthionine sulfoximine-mediated glutathione depletion.
    Friedman HS, Colvin OM, Griffith OW, Lippitz B, Elion GB, Schold SC, Hilton J, Bigner DD.
    J Natl Cancer Inst; 1989 Apr 05; 81(7):524-7. PubMed ID: 2921776
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Sensitive enzymatic cycling assay for glutathione: measurements of glutathione content and its modulation by buthionine sulfoximine in vivo and in vitro in human colon cancer.
    Berger SJ, Gosky D, Zborowska E, Willson JK, Berger NA.
    Cancer Res; 1994 Aug 01; 54(15):4077-83. PubMed ID: 8033140
    [Abstract] [Full Text] [Related]

  • 7. Effect of glutathione depletion by L-buthionine sulfoximine on the cytotoxicity of cyclophosphamide in single and fractionated doses to EMT6/SF mouse tumors and bone marrow.
    Ono K, Shrieve DC.
    J Natl Cancer Inst; 1987 Oct 01; 79(4):811-5. PubMed ID: 3477662
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors.
    Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS, Slovak ML, Rustum YM.
    Clin Cancer Res; 1996 Dec 01; 2(12):1961-8. PubMed ID: 9816155
    [Abstract] [Full Text] [Related]

  • 10. Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity.
    Liebmann JE, Hahn SM, Cook JA, Lipschultz C, Mitchell JB, Kaufman DC.
    Cancer Res; 1993 May 01; 53(9):2066-70. PubMed ID: 8097674
    [Abstract] [Full Text] [Related]

  • 11. Influence of buthionine sulfoximine and misonidazole on glutathione level and radiosensitivity of human tumor xenografts.
    Guichard M, Lespinasse F, Malaise EP.
    Radiat Res; 1986 Jan 01; 105(1):115-25. PubMed ID: 3945723
    [Abstract] [Full Text] [Related]

  • 12. Enhanced melphalan cytotoxicity in human ovarian cancer in vitro and in tumor-bearing nude mice by buthionine sulfoximine depletion of glutathione.
    Ozols RF, Louie KG, Plowman J, Behrens BC, Fine RL, Dykes D, Hamilton TC.
    Biochem Pharmacol; 1987 Jan 01; 36(1):147-53. PubMed ID: 3801051
    [Abstract] [Full Text] [Related]

  • 13. Hyperthermia-induced enhancement of melphalan activity against a melphalan-resistant human rhabdomyosarcoma xenograft.
    Laskowitz DT, Elion GB, Dewhirst MW, Griffith OW, Savina PM, Blum MR, Prescott DM, Bigner DD, Friedman HS.
    Radiat Res; 1992 Feb 01; 129(2):218-23. PubMed ID: 1734453
    [Abstract] [Full Text] [Related]

  • 14. Melphalan transport, glutathione levels, and glutathione-S-transferase activity in human medulloblastoma.
    Friedman HS, Skapek SX, Colvin OM, Elion GB, Blum MR, Savina PM, Hilton J, Schold SC, Kurtzberg J, Bigner DD.
    Cancer Res; 1988 Oct 01; 48(19):5397-402. PubMed ID: 3416297
    [Abstract] [Full Text] [Related]

  • 15. Lack of enhanced antitumor efficacy for L-buthionine sulfoximine in combination with carmustine, cyclophosphamide, doxorubicin or melphalan in mice.
    Soble MJ, Dorr RT.
    Anticancer Res; 1988 Oct 01; 8(1):17-22. PubMed ID: 3358633
    [Abstract] [Full Text] [Related]

  • 16. Buthionine sulfoximine-mediated depletion of glutathione in intracranial human glioma-derived xenografts.
    Skapek SX, Colvin OM, Griffith OW, Groothuis DR, Colapinto EV, Lee Y, Hilton J, Elion GB, Bigner DD, Friedman HS.
    Biochem Pharmacol; 1988 Nov 15; 37(22):4313-7. PubMed ID: 3196356
    [Abstract] [Full Text] [Related]

  • 17. Effect of DL-buthionine-S,R-sulfoximine on the growth of EMT6 and RIF mouse tumors.
    Miller AC, Henderson BW.
    J Natl Cancer Inst; 1986 Aug 15; 77(2):505-10. PubMed ID: 3461211
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The effect of L-buthionine-[S,R]-sulfoximine on the pancreas in mice. A model of weakening glutathione-based defense mechanisms.
    Lüthen RE, Neuschwander-Tetri BA, Niederau C, Ferrell LD, Grendell JH.
    Int J Pancreatol; 1994 Aug 15; 16(1):31-6. PubMed ID: 7528760
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.